Morepen Laboratories Ltd

Stage 2 · Advancing · week 22Setup 6.2 ★ FairEven −0.6

As of 20 Nov 2026, Morepen Laboratories is in Stage 2, the uptrend phase, now in week 22 (since 17 Jun 2026). It closed at ₹90.15, 38.7% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States… More about the company

₹90.2
Close, 20 Nov 2026
-0.68% on the day
₹4,940 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Uptrend, resting below its 50-day

Setup score

6.2 ★ Fair

RS rank

Edge

Even −0.6

MOREPENLAB is about 5 months into its Stage 2 advance, 22% below its 50-day average and 39% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.

Its relative strength is 95 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup at this point in their move ran 0.6 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 14% above entry.

The trend read holds while it stays in Stage 2. A close below ₹116, its 50-day average, would put it at rest; ₹118, 20% under its 52-week high of ₹147, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #38 of 50 in Pharmaceuticals · #47 of 61 in Health Care

Is MOREPENLAB early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 16w
S2 24w
S4 36w
S2 22w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 11w → S3 3w → S2 16w → S3 11w → S2 24w → S3 12w → S4 12w → S1 12w → S4 36w → S1 9w → S2 22w current
Total tracked: 169 weeks across 11 stage runs.

MOREPENLAB among Pharmaceuticals14th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…14MOREPENLABStage 2 · wk 2295−21.9%
vs 52W High
-38.7%
₹33.7 lo₹147 hi
38.7% below 52W high, far from high
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 22
1w13w26w
Week 22, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
30.7%
200 DMA: ₹69 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
0.16x
vs 50-day avg
Volume was well below average. In a Stage 2 advance, quiet sessions read as the stock resting, not being sold.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.9%
3M
+2.0%
6M
+112.0%
YTD
+119.5%
1Y
+93.5%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #15 of 58 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #12 of 48 Stage 2 stocks in this industry.

Mutual fund holdings

Held by 5 mutual funds in portfolios to October 2026: 1 active funds and 4 index funds and ETFs.

In October, among active funds: 1 opened a new position.

1 increased or opened0 reduced or exited
Largest active holders, by weight in the fund
All 5 funds and what each did in October

Mutual funds holding MOREPENLAB: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 29 Oct 2026
Last appeared 4 Sep 2026
Last appeared 17 Jun 2026
25 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S2
Wk 22 · Vol 0.16x
2026-11-19S2
Wk 22 · Vol 0.13x
2026-11-18S2
Wk 22 · Vol 0.17x
2026-11-17S2
Wk 21 · Vol 0.31x
2026-11-16S2
Wk 21 · Vol 0.31x
2026-11-13S2
Wk 21 · Vol 0.19x
2026-11-12S2
Wk 21 · Vol 0.22x
2026-11-11S2
Wk 21 · Vol 0.34x
2026-11-09S2
Wk 20 · Vol 0.46x
2026-11-06S2
Wk 20 · Vol 0.41x
2026-11-05S2
Wk 20 · Vol 0.74x
2026-11-04S2
Wk 20 · Vol 0.74x
Moving averages & range
50 DMA
₹115.8
200 DMA
₹69
52W High
₹147
52W Low
₹33.7
5D Low
₹90.2
Resistance levels (recent highs)
20d High
₹132.2
60d High
₹147
120d High
₹147
250d High
₹147
Next resistance
+46.6%
to 20d High
P/E (TTM)
29.0
Forward —
Earnings Growth (YoY)
+116.0%
Revenue +81.4%
ROE
+14.6%
Profit margin +8.2%
Dividend Yield
0.20%
P/B 4.0

Morepen Laboratories: quick answers

What stage is Morepen Laboratories in?

As of 20 Nov 2026, Morepen Laboratories (MOREPENLAB) is in Stage 2, the uptrend phase. It entered Stage 2 on 17 Jun 2026 and is in week 22. What the four stages mean

Is Morepen Laboratories in an uptrend?

Yes. Morepen Laboratories is in a Stage 2 uptrend. It trades 30.7% above its 200-day average, which is rising.

How far is Morepen Laboratories from its 52-week high?

Morepen Laboratories closed at ₹90.15 on 20 Nov 2026, 38.7% below its 52-week high of ₹147. Its 52-week low is ₹33.68.

How has Morepen Laboratories performed over the past year?

As of 20 Nov 2026, Morepen Laboratories is up 93.5% over the past year and up 119.5% so far in 2026.

Which sector and industry is Morepen Laboratories in?

Morepen Laboratories is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides OTC and healthcare products, including fever X for fever; Pain X for pain; Fiber-X for constipation; sat isabgol; Acidity X for acidity; Burnol, a first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. The company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.